Best Practices for Conquering the Enablement Requirement After Amgen
The Supreme Court’s decision in Amgen Inc. v. Sanofi found that antibody claims defined by their binding and blocking function lacked enablement....The consensus seems to be that Amgen generally forecloses broad genus claims in the biotechnology field.
Source: ipwatchdog.com